

### Sell – GlaxoSmithKline (GSK)

February 19, 2013

Leveraged products involve a high level of risk and you can lose more than your original investment. They are not suitable for everyone so please ensure you understand the risks involved and if necessary please obtain investment advice from a financial adviser before investing. This report is not a personal recommendation and does not take into account your personal circumstances or appetite for risk.

Trade parameters: Current Price 1470p	<b>Stop Loss</b> 20p away (1490p)	Limit/Target 1415p	Reward vs. Risk 2.8x	CFD Margin 5%
Technical Observations - For• Shares slowed up at rising trendline of resistance• RSI broken below trendline of support• RSI turned back from oversold• Momentum testing rising trendline of support• Falling volumes as momentum slowed			Technical Observations - Against• MACD not yet turned down below signal• ADX (trend strength) still very strong• Momentum not yet gone negative• Performance vs. FTSE100 been improving• Support from 200-day moving average (1415p) before target	

### News / Broker Comments / Important Dates / Observations \*\*

JV ViiV Healthcare says *Dolutegravir* for HIV, in combination with antivirals, granted FDA priority review (15 Feb). Fitch says does not expect large acquisitions by GSK, more likely AZN (14 Feb). Reuters says GSK amongst few considering 3-4bn deal for Brazilian drug-maker (13 Feb). Company's asks for accelerated authorization of *Trametinib* (7 Feb). Shares rose strongly after recent results (6 Feb), but momentum fallen since. **Next Event:** Ex-div, 20 Feb\*; Q1 results, 24 Apr *\*Trade parameters may need revising from tomorrow* 

Latest Broker 12m Consensus: 11 x Buy, 17 x Hold, 4 x Sell (Source: Digital Look & AlphaTerminal) (U = Upgrade / D = Downgrade) 19-Feb, JPMorgan, Underweight, TP 1460p; 12-Feb, BoA-ML, Buy, TP 1575p; 7-Feb, ExaneBNP, Underperform, TP 1400p; 7-Feb, Barclays, Overweight, TP 1510p; 7-Feb, UBS, Neutral, 1450p; 7-Feb, Jefferies, Hold, TP 1500p; 5-Feb, Nomura, TP1340p



#### Stock description

GlaxoSmithKline PLC is a research-based pharmaceutical company. The Company develops, manufactures, and markets vaccines, prescription, and over-the-counter medicines, as well as health-related consumer products. GlaxoSmithKline provides products for infections, depression, skin conditions, asthma, heart & circulatory disease, and cancer. (FTSE100)

### Graph: 2-year (daily)

Stock last used as Trade Idea; 24-Oct-2012

\*\***Source**: DowJones Newswires, Reuters News or Company Press releases, Bloomberg.com

Need help with Technical Analysis? Click

Our research is produced by Accendo Markets Limited. Research produced and disseminated by Accendo Markets is classified as non-independent research, and is therefore a marketing communication. Accendo Markets research has not been prepared in accordance with legal requirements designed to promote its independence and may not comply with FSA guidelines to prevent conflicts of interest and is not subject to any prohibition on dealing ahead of the dissemination of research. As such, this research does not constitute a personal recommendation or offer to enter into a transaction or an investment, and is produced and distributed for information purposes only. Accendo Markets considers information contained within the research to be valid when published, and gives no warranty as to the investments referred to in this material. The income from the investments referred to may go down as well as up, and investors may realise losses on investments. The past performance of a particular investment is not necessarily a guide to its future performance. Prepared by Michael van Dulken, Analyst

Accendo Markets Ltd is Authorised and Regulated by the Financial Services Authority (FSA) No. 475285. We offer CFD, SpreadBet and FX Trading Services Accendo Markets Ltd, Registered in England and Wales No. 6417051. Registered Office: 64 London Wall, London, EC2M 5TP, +44 (0) 20 3051 7461



# Sell – GlaxoSmithKline (GSK)

February 19, 2013

Leveraged products involve a high level of risk and you can lose more than your original investment. They are not suitable for everyone so please ensure you understand the risks involved and if necessary please obtain investment advice from a financial adviser before investing. This report is not a personal recommendation and does not take into account your personal circumstances or appetite for risk.



Graph: 2-year (daily) - ADX and Directional Indicators, MACD & Volume

Moving averages on price: Green: 200-period, Black: 100-period, Red: 50-period, Red: 20-period

Need help understanding this page? <u>Click</u>


Need help with Technical Analysis? Click



# Sell – GlaxoSmithKline (GSK)

February 19, 2013

Leveraged products involve a high level of risk and you can lose more than your original investment. They are not suitable for everyone so please ensure you understand the risks involved and if necessary please obtain investment advice from a financial adviser before investing. This report is not a personal recommendation and does not take into account your personal circumstances or appetite for risk.





Need help understanding this page? Click

Need help with Technical Analysis? Click